Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.

S Amadori,S Suciu,Roberto Stasi,R. Willemze,Franco Mandelli,D Selleslag,Claudio Denzlinger,P. Muus,R. Stauder,Zwi N. Berneman,J.F.M. Pruijt,F. Nobile,V. Cassibba,J.P. Marie,F Beeldens,Liliana Baila,Marco Vignetti,T.J.M. de Witte

Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.

2005

S Amadori
S Suciu
Roberto Stasi
R. Willemze
Franco Mandelli
D Selleslag
Claudio Denzlinger
P. Muus
R. Stauder
Zwi N. Berneman
J.F.M. Pruijt
F. Nobile
V. Cassibba
J.P. Marie
F Beeldens
Liliana Baila
Marco Vignetti
T.J.M. de Witte

Gemtuzumab ozogamicin (Mylotarg ® ) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups

Keywords:

Cancer research
Myeloid leukemia
Hematology
Phases of clinical research
Cancer
Gemtuzumab ozogamicin
Leukemia
Chemotherapy
Calicheamicin
Medicine
Internal medicine
Surgery
CD33

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations